NASDAQ:OBLN - Obalon Therapeutics Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
▼ -0.16 (-3.67%)

This chart shows the closing price for OBLN by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Obalon Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for OBLN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for OBLN

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 1 analysts offering 12 month price targets for Obalon Therapeutics in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $4.20.

This chart shows the closing price for OBLN for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 1 investment analysts is to buy stock in Obalon Therapeutics. This rating has held steady since March 2020, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart

  • 0 strong buy ratings
  • 1 buy ratings
  • 3 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/18/2021Alliance Global PartnersUpgradeNeutral ➝ BuyLow
3/27/2020Alliance Global PartnersDowngradeBuy ➝ NeutralMedium
7/24/2019Northland SecuritiesReiterated RatingHoldMedium
7/11/2019Northland SecuritiesReiterated RatingHold$10.00Low
4/11/2019Northland SecuritiesReiterated RatingHold$10.00Low
4/8/2019Canaccord GenuityDowngradeBuy ➝ Hold$30.00 ➝ $15.00High
2/26/2019Roth CapitalReiterated RatingBuy ➝ Neutral$60.00 ➝ $27.50High
2/25/2019Stifel NicolausUpgradeHold ➝ Buy$25.00 ➝ $30.00High
2/5/2019Roth CapitalReiterated RatingBuyMedium
1/3/2019Northland SecuritiesReiterated RatingHold$20.00Low
9/12/2018Northland SecuritiesReiterated RatingHold$25.00Medium
9/12/2018BTIG ResearchReiterated RatingBuy$35.00Low
9/11/2018Stifel NicolausBoost Price TargetHold ➝ Hold$25.00 ➝ $35.00Low
9/6/2018Roth CapitalInitiated CoverageBuy$60.00High
8/5/2018BTIG ResearchReiterated RatingBuyLow
8/3/2018Stifel NicolausLower Price TargetHold ➝ Hold$30.00 ➝ $20.00High
8/2/2018Northland SecuritiesUpgradeUnderperform ➝ Market PerformHigh
5/11/2018Stifel NicolausDowngradeBuy ➝ HoldLow
5/11/2018Northland SecuritiesDowngradeMarket Perform ➝ UnderperformHigh
3/6/2018Stifel NicolausReiterated RatingBuyHigh
3/6/2018BTIG ResearchLower Price TargetBuy$70.00High
3/6/2018Canaccord GenuityReiterated RatingBuy ➝ Buy$110.00 ➝ $100.00High
2/21/2018Northland SecuritiesReiterated RatingHold$40.00Low
1/25/2018Northland SecuritiesUpgradeUnderperform ➝ Market PerformMedium
1/23/2018Northland SecuritiesReiterated RatingSell$40.00Medium
1/22/2018Canaccord GenuityReiterated RatingPositive ➝ Buy$150.00 ➝ $110.00Low
11/16/2017BTIG ResearchReiterated RatingBuy$150.00N/A
11/10/2017UBS GroupLower Price TargetBuy$200.00 ➝ $160.00N/A
11/6/2017BTIG ResearchLower Price TargetBuy ➝ Buy$200.00 ➝ $150.00N/A
11/3/2017Northland SecuritiesReiterated RatingSell$40.00N/A
8/9/2017UBS GroupReiterated RatingBuy$220.00 ➝ $200.00Low
8/3/2017UBS GroupReiterated RatingBuy$220.00 ➝ $200.00Medium
8/2/2017Northland SecuritiesReiterated RatingSell$60.00Medium
6/21/2017Northland SecuritiesInitiated CoverageUnder Perform$60.00High
5/18/2017Canaccord GenuityReiterated RatingBuyLow
4/17/2017Canaccord GenuityReiterated RatingBuyMedium
3/19/2017BTIG ResearchReiterated RatingBuy$200.00Medium
2/9/2017Canaccord GenuitySet Price TargetBuy$170.00N/A
1/23/2017Canaccord GenuityReiterated RatingBuy$170.00N/A
11/11/2016Canaccord GenuitySet Price TargetBuy$170.00N/A
10/31/2016Stifel NicolausInitiated CoverageBuy$180.00N/A
10/31/2016Canaccord GenuityInitiated CoverageBuy$280.00N/A
10/31/2016BTIG ResearchInitiated CoverageBuy$200.00N/A
10/31/2016UBS GroupInitiated CoverageBuy$210.00N/A
(Data available from 7/24/2016 forward)
Obalon Therapeutics logo
Obalon Therapeutics, Inc., a vertically integrated medical device company, focuses on developing and commercializing medical devices to treat people with obesity. The company offers the Obalon Balloon System designed to provide weight loss in patients with obesity. Its Obalon Balloon System comprises of a swallowable capsule that contains an inflatable balloon attached to a microcatheter; the Obalon Navigation System console, which is a combination of hardware and software used to track and display the location of the balloon during placement; the Obalon Touch Inflation Dispenser, which is a semi-automated, hand-held inflation device used to inflate the balloon once it is placed; and a disposable canister filled with mixture of gas. Obalon Therapeutics, Inc. was incorporated in 2008 and is headquartered in Carlsbad, California.
Read More

Today's Range

Now: $4.20
Low: $4.10
High: $4.50

50 Day Range

MA: $4.22
Low: $2.36
High: $7.64

52 Week Range

Now: $4.20
Low: $0.66
High: $10.77


5,591,081 shs

Average Volume

7,677,330 shs

Market Capitalization

$42.09 million

P/E Ratio


Dividend Yield




Frequently Asked Questions

What sell-side analysts currently cover shares of Obalon Therapeutics?

The following Wall Street sell-side analysts have issued stock ratings on Obalon Therapeutics in the last twelve months: Alliance Global Partners.
View the latest analyst ratings for OBLN.

What is the current price target for Obalon Therapeutics?

0 Wall Street analysts have set twelve-month price targets for Obalon Therapeutics in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Obalon Therapeutics in the next year.
View the latest price targets for OBLN.

What is the current consensus analyst rating for Obalon Therapeutics?

Obalon Therapeutics currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe OBLN will outperform the market and that investors should add to their positions of Obalon Therapeutics.
View the latest ratings for OBLN.

What other companies compete with Obalon Therapeutics?

How do I contact Obalon Therapeutics' investor relations team?

Obalon Therapeutics' physical mailing address is 5421 Avenida Encinas Suite F, Carlsbad CA, 92008. The company's listed phone number is (844) 362-2566 and its investor relations email address is [email protected] The official website for Obalon Therapeutics is